Redeye leaves a comment following OncoZenge’s announcement of a collaboration with UCLA, marking an important first step toward a potential future US market entry for BupiZenge. We view this initiative as a strategically sound move that broadens the scope of the program beyond Europe, while also providing valuable patient insights to support future regulatory and clinical planning in the US.
LÄS MER
